Pharmaceutical companies have one major problem, poor bioavailability stops drugs getting to the market. Solving this problem takes a long time, costs a lot of money and reduces highly profitable patent life. This is a €9.2 billion market.
SeraNovo’s proprietary formulation platform radically increases bioavailability and allows products to reach the market significantly quicker, at a lower cost.
For every drug, SeraNovo creates a purpose designed eutectic mixture and couples it with polymers to create a formulation. When orally administered these formulations create a supersaturated state in the intestine resulting in a significantly higher bioavailability.
SeraNovo is seeking an investment of €600,000 to validate the technology and establish the first two licence agreements. In year 5 SeraNovo will have established 14 licence agreements with major pharmaceutical companies. Successful licence agreements will lead to a % of net sales when the licensee’s drug reaches the market
Co-founders Niall Hodgins (Biology MSc) and Bastiaan Kluft (Chemistry MSc) are the technology inventors. Ian Degeling (Chemistry MSc) is a DES formulation expert while Joost Holthuis and Erik Frijlink are the principle advisors on strategy and technology respectively.
- Venture Challenge Fall 2018
Niall Hodgins | info[at]seranovo[dot]com